Ogeda S.A.
11 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1
Ending by 2030
Jun 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jul 28, 2027The maintenance fee for NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders (US 10,544,150) comes due Jul 28, 2027. Unpaid by Jan 28, 2028, it lapses early.
- 1 fee due Oct 21, 2027The maintenance fee for NK-3 Receptor Antagonists for Therapeutic or Cosmetic Treatment of Excess Body Fat (US 10,624,890) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 22, 2026
- Oct 15 US 7,582,416 Ligand for G-Protein Coupled Receptor FPRL2 and Uses Thereof · term ended
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,824,866 | Ligand for G-protein coupled receptor GPR72 and uses thereof In force · USPTO record | In force | USPTO record | |
| US 8,871,761 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders In force · USPTO record | In force | USPTO record | |
| US 9,926,325 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders In force · USPTO record | In force | USPTO record | |
| US 10,065,960 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders In force · USPTO record | In force | USPTO record | |
| US 10,544,150 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders In force · USPTO record | In force | USPTO record | |
| US 9,475,814 | Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof In force · USPTO record | In force | USPTO record | |
| US 10,065,961 | Chiral N-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof In force · USPTO record | In force | USPTO record | |
| US 10,683,295 | Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-A]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof In force · USPTO record | In force | USPTO record | |
| US 10,941,151 | Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof In force · USPTO record | In force | USPTO record | |
| US 9,840,508 | N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a] pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 19: 11 patents in force now held by others · 28 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 no status recorded
Showing 1 to 3 of 3, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. No title is shown: the bulk publication record carries none for these applications, and this site holds no USPTO file history for them.
| Application | Filed | Status |
|---|---|---|
| 18/235,976 | Aug 21, 2023 | No status recorded |
| 16/722,353 | Dec 20, 2019 | No status recorded |
| 15/512,919 | Sep 25, 2015 | No status recorded |